Prostate Cancer – What All Men Must Know!

Immune modulation is achieved by actively stimulating cellular immunity by increasing endorphin production by feedback phenomenon, late in the night to early morning. These activated cells then attack the cells implicated in various disease states.

This is a topic that everyone who is passionate about his field of specialization would go to any length to defend. However, to a lay person on the street with cancer or with family members affected by cancer, the most important issue is, which of this can put cancer at bay permanently without the daily grind and untold financial, emotional, physical and family hardships that go with the diagnosis!

Gene therapy (the use of DNA to supplement or alter genes in the individual affected) is here to stay although it has not proven to be as effective considering the hype that came with the introduction in 1990 when Ashanti DeSilva was first treated. The prohibitive cost is also of significance as it is not something that was readily available and accessible by the masses.

Immune modulation is achieved by actively stimulating cellular immunity by increasing endorphin production by feedback phenomenon, late in the night to early morning. These activated cells then attack the cells implicated in various disease states. These conditions include HIV, cancer, allergy, resistant Tuberculosis, typhoid, malaria, crohn’s disease, autoimmunity, chronic fatigue, immune dysfunction, multiple sclerosis, autism etc. There are a variety of drugs that have shown promise in this regard. One good example is Low Dose Naltrexone (Lodonal 4.5mg) the observation of which was started by Dr. Bernard Bihari. In our future discussions, more in-depth information about low dose naltrexone would be provided.

At American Hospitals, we not only provide patients with the best possible care, but also maintain an extensive research program.
We focus on basic laboratory research, translational research that bridges discoveries made in the laboratory and those made in the clinic, as well as mathematical and computational research which is directed at analyzing and interpreting biomedical data.Within our research program, there are three key areas Design and Analysis Clinical Research and Development and Operations.  Our goal is to identify and solve clinical challenges, whether it’s devising new surgical techniques, discovering innovative therapies, or developing new processes to safely reduce HIV/Aids, cancer and blood disorder cases. We are currently undertaking a 90-Day bridging clinical trial for LODONAL™ ; Naltrexone hydrochloride (HCl), 4.5 mg titled : A Bridging Study to Evaluate the Effects of LODONAL as an Immune-System Regulating Agent in Subjects, in which their Immune System is Compromised with State Hospital, Asubiaro, Osogbo, Osun State, Nigeria as our trial center. This is a single center, open-label, randomized bridging study to confirm the safety and efficacy of LODONAL in a Nigerian population. Eligible subjects will be randomly assigned to enter into one of two treatment arms:

The first group of eligible subjects (approximately 75) will be treated in an open-label manner with 4.5 mg doses of LODONAL once daily for 90 days (Group A). A second group (controls) of eligible subjects will have delayed therapy with an observation period, whereby the subjects will not be treated during the first 90 days but observed; then the subjects will be treated with LODONAL 4.5 mg once daily for 90 days in an open-label treatment (Group B). Both groups will continue with their standard of care treatment in addition to taking LODONAL during this study.